Bimatoprost acid

TargetMol
Product Code: TAR-T20939
Supplier: TargetMol
CodeSizePrice
TAR-T20939-1mg1mg£196.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T20939-5mg5mg£328.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T20939-1mL1 mL * 10 mM (in DMSO)£390.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T20939-10mg10mg£452.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T20939-25mg25mg£696.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T20939-50mg50mg£946.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T20939-100mg100mg£1,251.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
Prices exclude any Taxes / VAT

Overview

Regulatory Status: RUO
Shipping:
cool pack
Storage:
-20℃

Images

1 / 1

Further Information

Bioactivity:
Bimatoprost acid is a metabolically stable analog of PGF2α and has a potential antagonistic activity for the FP receptor. It has a relative potency of 756% compared to PGF2α for binding to the FP receptor on ovine luteal cells.
CAS:
38344-08-0
Formula:
C23H32O5
Molecular Weight:
388.504
Pathway:
Endocrinology/Hormones; GPCR/G Protein
Purity:
0.98
SMILES:
O[C@@H](CCc1ccccc1)C=C[C@H]1[C@H](O)C[C@H](O)[C@@H]1CC=C/CCCC(O)=O
Target:
GPR

References

1. 1.Yulia K , Kinuthia M W , Thoa T , et al. New Human Organotypic Corneal Tissue Model for Ophthalmic Drug Delivery Studies[J]. Investigative Ophthalmology & Visual Science, 2018, 59(7):2880-2898. 2. Klimko PG, Sharif NA. Discovery, characterization and clinical utility of prostaglandin agonists for the treatment of glaucoma. Br J Pharmacol. 2018 Apr 17. doi: 10.1111/bph.14327. [Epub ahead of print] Review. PubMed PMID: 29665040. 3. Shen J, Goodkin ML, Tong W, Attar M. Ocular pharmacokinetics and tolerability of bimatoprost ophthalmic solutions administered once or twice daily in rabbits, and clinical dosing implications. Clin Ophthalmol. 2017 Sep 28;11:1761-1767. doi: 10.2147/OPTH.S143428. eCollection 2017. Erratum in: Clin Ophthalmol. 2018 Aug 17;12:147PubMed PMID: 29026287; PubMed Central PMCID: PMC5627754. 4. Krupa M, Chody?ski M, Ostaszewska A, Cmoch P, Dams I. A Novel Convergent Synthesis of the Potent Antiglaucoma Agent Tafluprost. Molecules. 2017 Jan 31;22(2). pii: E217. doi: 10.3390/molecules22020217. PubMed PMID: 28146132.